Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer

  title={Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer},
  author={Chang Moo Kang and Ho Kyoung Hwang and Jiae Park and Chang Young Kim and Seong-Kyoung Cho and Mijin Yun and Woo Jung Lee},
AbstractThis study investigated the oncologic impact of loss of SMAD4 expression in resected left-sided pancreatic cancer and its correlation with tumor metabolism.From 2005 to 2011, the medical records of patients who underwent radical distal pancreatectomy for resectable pancreatic cancer were retrospectively reviewed. Formalin-fixed, paraffin embedded tissue from 32 patients was investigated. Clinicopathological characteristics, immunostaining of SMAD4, and positron emission tomography-based… 

Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis

Transcriptome-wide analysis revealed that tumors with MTV2.5 demonstrated significantly different expression of cancer-related genes reflecting aggressive tumor biology, which might need to be considered when managing resectable pancreatic cancers.

Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail.

Although few in patient numbers, this data suggests integration of adjuvant RT in resected pancreatic tail adenocarcinoma may improve OS.

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.

In patients with resected PDAC, genomic alterations in KRAS and TP53 are associated with worse outcomes, whereas alterations in HRD genes are associatedWith a favorable prognosis.

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy

CDKN2B, FAT3, MTAP, and SMAD4 may be biomarkers that distinguish primary tumors from metastases and EPHA7 mutation may serve as a prognostic biomarker to predict the treatment efficacy of AG chemotherapy in locally advanced pancreatic cancer.

Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer

Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome

In chemo-naïve resected PDAC, combinations of mutations in the four driver genes are associated with prognosis and in patients with combined mt KRAS and mt TP53 , KRAS p.G12D variant confers a better OS and RFS.

SMAD4 Y353C promotes the progression of PDAC

This study supports the key role of SMad4 as a tumour suppressor gene in PDAC and shows that SMAD4 Y353C is associated with poor progression of PDAC.

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel

This work highlights that the combination of KRAS mutation with the age of the patient and the lymph node status may help in predicting the outcome in PDAC patients.

Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment

The genomic variations in pancreatic cancer are discussed, and the resulting potential diagnostic and therapeutic implications are discussed.



Failure Patterns in Resected Pancreas Adenocarcinoma: Lack of Predicted Benefit to SMAD4 Expression

Primary tumor SMAD4 expression status was not a predictor of recurrence pattern in a large cohort of patients with resected PDA.

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients with Pancreatic Cancer

18F-FDG PET/CT can provide useful prognostic information for patients undergoing resection of pancreatic cancer with curative intent irrespective of neoadjuvant treatment, and MTV and TLG are independent prognostic factors for predicting RFS and OS in patients with Pancreatic cancer.

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer

The case for immunohistochemical expression of VEGF representing a significant and reproducible marker of adverse prognosis in resected pancreatic cancer is supported, and the overall prognostic effect is quantified.

Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer

Multivariate analysis of OS and DFS showed that degree of FDG uptake was an independent prognostic factor in pancreatic cancer patients who underwent curative resection, and both high SUVmax and poor tumor differentiation were independent poor prognostic factors.

DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.

  • A. BiankinA. Morey S. Henshall
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Prognostic indicators in pancreatic cancer are poorly defined and difficult to quantify preoperatively, hence they may lead to inappropriate patient selection for treatment and accurate assessment of DPC4/Smad4 expression, unlike tumor size, margin status, and perineural invasion, does not require resection.

Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection

MTV and TLG showed strong consistency with baseline serum CA19-9 level in better predicting OS and RFS, and might serve as surrogate markers for prediction of outcome in patients with resectable PDAC.

Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic 18F-FDG PET/CT

Quantitative 18F-FDG kinetic parameters measured by dynamic PET in newly diagnosed pancreatic cancer correlated with the aggressiveness of disease.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Pancreatic cancers are represented by distinct genetic subtypes with significantly different patterns of failure, and determinations of DPC4 status at initial diagnosis may be of value in stratifying patients into treatment regimens related to local control versus systemic therapy.

Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer

Genetic alterations of these 3 genes and their accumulation are strongly associated with malignant behavior of PDAC and may provide a new prognostic tool, assisting in deciding optimal therapeutic strategies for patients.

PET/CT of cancer patients: part 1, pancreatic neoplasms.

Early data suggest that contrast-enhancedPET/CT performed with modern PET/CT scanners yields high-resolution anatomic information for surgical and radiotherapeutic planning and functional information for whole-body staging in the care of patients with this disease.